促红细胞生成素在急性肾功能衰竭患者中临床应用观察.docVIP

促红细胞生成素在急性肾功能衰竭患者中临床应用观察[摘要] 目的：了解促红细胞生成素治疗对于急性肾功能衰竭患者肾衰竭临床指标及预后的影响。方法：急性肾功能衰竭患者共42例，分为两组，治疗组在基础治疗的基础上，给予促红细胞生成素5 000 U，每周2次，对比两组患者少尿期持续时间、肌酐减半时间、血红蛋白、红细胞压积、白蛋白等指标。结果：促红细胞生成素治疗组比对照组患者少尿期有所缩短（P 1.4 统计学处理 数据以均数±标准差（x±s）表示，采用SPSS 10.0 统计软件进行统计学处理，参数比较使用t检验、?字2检验，以P＜0.05为差异有统计学意义。 2 结果 2.1 两组患者的一般资料 两组患者一般资料无显著性差异，具有可比性，见表1。 表1 两组患者的一般资料（例） 2.2 两种治疗对急性肾功能衰竭患者肾脏功能恢复临床指标的影响 治疗后1个月两组对比指标见表2。常规治疗组少尿期持续（12.6±6.5） d，治疗组为（10.8±5.7） d，少尿期有所缩短。治疗组最高肌酐水平减半时间较常规治疗组缩短，差异有统计学意义（P [6]Mitra A, Bansal S, Wang W, et al. Erythropoietin ameliorates renal dysfunction during endotoxaemia [J]. Nephrol Dial Transplant,2007,22(8):2349-2353. [7]Salahudeen AK, Haider N, Jenkins J, et al. Anti-apoptotic properties of erythropoiesis stimulating proteins in models of cisplatin-induced acute kidney injury [J]. Am J Physiol Renal Physiol,2008,294(6:):F1354-1365. [8]Sharples EJ, Yaqoob M. Erythropoietin in experimental acute renal failure [J]. Nephron Exp Nephrol,2006,104(3):e83-88. [9]Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin [J]. Nat Clin Pract Nephrol,2005,1(2):87-97. [10]Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure [J]. Kidney Int,2006,69(10):1806-1813. [11]Sturiale A, Campo S, Crascì E. Experimental models of acute renal failure and erythropoietin: what evidence of a direct effect？[J]. Ren Fail,2007,29(3):379-386. [12]Goldfarb M, Rosenberger C, Ahuva S. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats [J]. Ren Fail,2006,28(4):345-350. [13]Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model [J]. Nephrol Dial Transplant,2006,21(2):330-336. [14]Park J, Gage BF, Vijayan A. Use